2-氨基-3,5-二氢吡咯并[3,2-D]嘧啶-4-酮 | 65996-58-9

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 2-氨基-3,5-二氢吡咯并[3,2-D]嘧啶-4-酮
• 英文名称: 9-deazaguanine
• 英文别名: 2-amino-5H-pyrrolo[3,2-d]pyrimidin-4(3H)-one；9-Deazaguanine；2-amino-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
• CAS: 65996-58-9
• 化学式: C₆H₆N₄O
• mdl: MFCD09540493
• 分子量: 150.14
• InChiKey: FFYPRJYSJODFFD-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C(Solv: water (7732-18-5))
• 密度：
  1.87±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.3
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氨基-3,5-二氢吡咯并[3,2-D]嘧啶-4-酮 在 sodium hydroxide 、 三氟甲磺酸 、 肼 作用下， 以 乙二醇 为溶剂， 反应 64.0h， 生成 2-amino-3H,5H-7-benzylpyrrolo[3,2-d]pyrimidin-4-one
  参考文献：
  名称：

  轻松合成9-取代的9-脱氮嘌呤类化合物作为潜在的嘌呤核苷磷酸化酶抑制剂。

  摘要：

  通过使用三氟甲磺酸作为催化剂对9-脱氮嘌呤进行直接的Friedel-Crafts芳基化或芳基甲基化反应，已经实现了9取代的9-脱氮嘌呤类化合物作为嘌呤核苷磷酸化酶潜在抑制剂的简便合成。可以通过Wolff-Kishner反应将芳酰化的9-脱氮嘌呤类化合物转化为相应的9-芳基甲基衍生物。还通过在三氟乙酸（TFA）中用原甲酸三乙酯处理4-羟基-5-苯基偶氮-6-甲基嘧啶-2-硫酮，开发了9-脱氮杂黄嘌呤的新型合成方法，从而制得8-oxo-7H-2-苯基嘧啶[5]。 ，4-c]哒嗪-6-硫酮，然后阮内镍还原。

  DOI：

  10.1248/cpb.50.364
• 作为产物：
  描述：

  2-氨基-6-甲基-5-硝基-3H-嘧啶-4-酮 在 sodium dithionite 作用下， 反应 24.5h， 生成 2-氨基-3,5-二氢吡咯并[3,2-D]嘧啶-4-酮
  参考文献：
  名称：

  9-Benzoyl 9-deazaguanines as potent xanthine oxidase inhibitors

  摘要：

  A novel potent xanthine oxidase inhibitor, 3-nitrobenzoyl 9-deazaguanine (LSPN451), was selected from a series of 10 synthetic derivatives. The enzymatic assays were carried out using an on-flow bidimensional liquid chromatography (2D LC) system, which allowed the screening, the measurement of the kinetic inhibition constant and the characterization of the inhibition mode. This compound showed a non-competitive inhibition mechanism with more affinity for the enzyme-substrate complex than for the free enzyme, and inhibition constant of 55.1 +/- 9.80 nM, about thirty times more potent than allopurinol. Further details of synthesis and enzymatic studies are presented herein. (c) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.006

文献信息

• Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
  申请人：——

  公开号：US20020147160A1

  公开（公告）日：2002-10-10

  The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

  本发明提供了核苷化合物及其某些衍生物，这些衍生物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂，可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶的抑制剂，作为HCV复制的抑制剂，以及/或用于治疗丙型肝炎感染。本发明还描述了包含这种核苷化合物的药物组合物，单独使用或与其他对RNA依赖性RNA病毒感染，特别是HCV感染有效的制剂组合使用。还公开了使用本发明的核苷化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• Oligonucleotides having modified nucleoside units
  申请人：——

  公开号：US20040014957A1

  公开（公告）日：2004-01-22

  Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

  披露的是包括一个或多个修饰核苷单元的寡核苷酸和寡核苷糖。这些寡核苷酸和寡核苷糖特别适用于作为反义剂、核酶、适配体、siRNA试剂、探针和引物，或者当它们与RNA杂交时，作为包括RNase H和dsRNase的RNA切割酶的底物。
• [EN] HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA GTP CYCLOHYDROLASE 1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：HERCULES TECHNOLOGY MAN CO V INC

  公开号：WO2011035009A1

  公开（公告）日：2011-03-24

  The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

  本发明涉及小分子杂环抑制剂对GTP环化酶（GCH-I）的，或其互变异构体、前药或药用可接受盐。该发明还涉及这些化合物的药物组合物以及这些化合物用于治疗或预防疼痛（例如炎症性疼痛、伤害性疼痛、功能性疼痛或神经病理性疼痛）的医疗用途。
• Process for preparing 2-pyrrolidinyl-1H-pyrrolo&lsqb;3,2-d&rsqb;pyrimidine inhibitors of nucleoside metabolism
  申请人：Industrial Research Limited

  公开号：US06693193B1

  公开（公告）日：2004-02-17

  A process of preparing a compound of the formula (I) wherein B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and Z is selected from OH, hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted all, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof, which comprises reacting a compound of the formula (II)  with an anion produced by abstraction of the bromine or iodine atom from a compound of formula (XIX),  to form a compound of formula (XX) The compound of formula (XX) is N- and O-deprotected to obtain the compound of formula (I).

  将公式（I）的化合物制备过程翻译成中文： 其中B选择自OH、NH2、NHR、H或卤素；D选择自OH、NH2、NHR、H、卤素或SCH3；R是可选择取代的烷基、芳基烷基或芳基；Z选择自OH、氢、卤素、羟基、SQ或OQ，Q是可选择取代的烷基、芳基烷基或芳基；或其互变异构体；或其药学上可接受的盐；或其酯；或其前药，包括将公式（II）的化合物与通过从公式（XIX）的化合物中提取溴或碘原子而产生的负离子反应，形成公式（XX）的化合物。公式（XX）的化合物经N-和O去保护得到公式（I）的化合物。
• [EN] OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS<br/>[FR] OLIGONUCLEOTIDES A UNITES NUCLEOSIDIQUES MODIFIEES
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2003099840A1

  公开（公告）日：2003-12-04

  Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

  揭示了包含一个或多个修饰核苷酸单元的寡核苷酸和寡核苷苷。这些寡核苷酸和寡核苷苷特别适用作为反义物质、核酶、适配体、siRNA物质、探针和引物，或者在与RNA杂交时，作为RNA裂解酶（包括RNase H和dsRNase）的底物。

表征谱图